EGFR and glioblastoma: The third-generation EGFR inhibitor osimertinib (AZD9291) and GDC-0084 have demonstrated greater permeability in a Phase I dose-escalation study conducted in patients with high-grade GBM (Ballard et al., 2016; Wen et al., 2020).